205 related articles for article (PubMed ID: 12524666)
1. Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition.
Nagakura T; Yasuda N; Yamazaki K; Ikuta H; Tanaka I
Metabolism; 2003 Jan; 52(1):81-6. PubMed ID: 12524666
[TBL] [Abstract][Full Text] [Related]
2. Metformin causes reduction of food intake and body weight gain and improvement of glucose intolerance in combination with dipeptidyl peptidase IV inhibitor in Zucker fa/fa rats.
Yasuda N; Inoue T; Nagakura T; Yamazaki K; Kira K; Saeki T; Tanaka I
J Pharmacol Exp Ther; 2004 Aug; 310(2):614-9. PubMed ID: 15039452
[TBL] [Abstract][Full Text] [Related]
3. [Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].
Diamant M; Bunck MC; Heine RJ
Ned Tijdschr Geneeskd; 2004 Sep; 148(39):1912-7. PubMed ID: 15495988
[TBL] [Abstract][Full Text] [Related]
4. Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes.
Wiedeman PE; Trevillyan JM
Curr Opin Investig Drugs; 2003 Apr; 4(4):412-20. PubMed ID: 12808880
[TBL] [Abstract][Full Text] [Related]
5. The combination of metformin and a dipeptidyl peptidase IV inhibitor prevents 5-fluorouracil-induced reduction of small intestine weight.
Yamazaki K; Yasuda N; Inoue T; Nagakura T; Kira K; Saeki T; Tanaka I
Eur J Pharmacol; 2004 Mar; 488(1-3):213-8. PubMed ID: 15044053
[TBL] [Abstract][Full Text] [Related]
6. Valine pyrrolidide preserves intact glucose-dependent insulinotropic peptide and improves abnormal glucose tolerance in minipigs with reduced beta-cell mass.
Larsen MO; Rolin B; Ribel U; Wilken M; Deacon CF; Svendsen O; Gotfredsen CF; Carr RD
Exp Diabesity Res; 2003; 4(2):93-105. PubMed ID: 14630571
[TBL] [Abstract][Full Text] [Related]
7. Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats.
Nagakura T; Yasuda N; Yamazaki K; Ikuta H; Yoshikawa S; Asano O; Tanaka I
Biochem Biophys Res Commun; 2001 Jun; 284(2):501-6. PubMed ID: 11394909
[TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes.
Deacon CF; Holst JJ
Int J Biochem Cell Biol; 2006; 38(5-6):831-44. PubMed ID: 16242377
[TBL] [Abstract][Full Text] [Related]
9. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.
Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
Eur J Pharmacol; 2008 Jul; 588(2-3):325-32. PubMed ID: 18499100
[TBL] [Abstract][Full Text] [Related]
10. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice.
Ahrén B; Holst JJ; Mårtensson H; Balkan B
Eur J Pharmacol; 2000 Sep; 404(1-2):239-45. PubMed ID: 10980284
[TBL] [Abstract][Full Text] [Related]
11. Enhanced secretion of glucagon-like peptide 1 by biguanide compounds.
Yasuda N; Inoue T; Nagakura T; Yamazaki K; Kira K; Saeki T; Tanaka I
Biochem Biophys Res Commun; 2002 Nov; 298(5):779-84. PubMed ID: 12419322
[TBL] [Abstract][Full Text] [Related]
12. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice.
Wang Q; Brubaker PL
Diabetologia; 2002 Sep; 45(9):1263-73. PubMed ID: 12242459
[TBL] [Abstract][Full Text] [Related]
14. Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery.
Chae SY; Jin CH; Shin HJ; Youn YS; Lee S; Lee KC
Bioconjug Chem; 2008 Jan; 19(1):334-41. PubMed ID: 18078308
[TBL] [Abstract][Full Text] [Related]
15. 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity.
Yamazaki K; Yasuda N; Inoue T; Nagakura T; Kira K; Shinoda M; Saeki T; Tanaka I
J Pharmacol Exp Ther; 2006 Dec; 319(3):1253-7. PubMed ID: 16980568
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl peptidase-IV inhibitors can restore glucose homeostasis in type 2 diabetics via incretin enhancement.
Mest HJ
Curr Opin Investig Drugs; 2006 Apr; 7(4):338-43. PubMed ID: 16625820
[TBL] [Abstract][Full Text] [Related]
17. Adenoviral vector-mediated glucagon-like peptide 1 gene therapy improves glucose homeostasis in Zucker diabetic fatty rats.
Lee Y; Kwon MK; Kang ES; Park YM; Choi SH; Ahn CW; Kim KS; Park CW; Cha BS; Kim SW; Sung JK; Lee EJ; Lee HC
J Gene Med; 2008 Mar; 10(3):260-8. PubMed ID: 18085721
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion.
Lugari R; Dei Cas A; Ugolotti D; Barilli AL; Camellini C; Ganzerla GC; Luciani A; Salerni B; Mittenperger F; Nodari S; Gnudi A; Zandomeneghi R
Horm Metab Res; 2004 Feb; 36(2):111-5. PubMed ID: 15002062
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice.
Kim SJ; Nian C; Doudet DJ; McIntosh CH
Diabetes; 2008 May; 57(5):1331-9. PubMed ID: 18299314
[TBL] [Abstract][Full Text] [Related]
20. Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice.
Matsuyama-Yokono A; Tahara A; Nakano R; Someya Y; Shiraki K; Hayakawa M; Shibasaki M
Metabolism; 2009 Mar; 58(3):379-86. PubMed ID: 19217455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
